Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Bilateral optic neuritis in a patient with Behçet's disease who respond to therapeutic plasma exchange.
Autoantibodies and pain.
Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.
CCL genes in multiple sclerosis and systemic lupus erythematosus.
Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis.
Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis.
[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].
[Flow cytometry model for the detection of neutralizing antibodies against of IFN-β].
Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions.
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
Optical Coherence Tomography: A Potential Noninvasive Follow-up Tool in Multiple Sclerosis.
Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008.
Prevalence of Multiple Sclerosis in the Republic of Moldova.
The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Effect of smoking on multiple sclerosis: a meta-analysis.
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.

Pages